Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals RNS Release

Notice of Q4 and year-end results

RNS Number : 4818Q
GW Pharmaceuticals PLC
30 November 2016
 

 

GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 5 December, 2016

 

London, UK, 30 Nov 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December, 2016 its fourth quarter and year-end financial results for the period ending 30 September, 2016. GW will also host a conference call the same day at 8:00 a.m. EST (1:00 p.m. GMT). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

 

About GW Pharmaceuticals plc

 

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

 

Enquiries:

 

GW Pharmaceuticals plc


Stephen Schultz, VP Investor Relations (U.S.)

917 280 2424 / 401 500 6570



FTI Consulting (Media Enquiries)


Ben Atwell / Simon Conway

+44 20 3727 1000

 

Peel Hunt LLP (UK NOMAD)


 

James Steel

+44 20 7418 8900

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORUKAKRNNAAUAA



GW Pharmaceuticals Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use